Investing.com -- Novo Nordisk (NYSE: NVO )’s guidance reduction and CEO resignation represent a "double surprise" according to BMO Capital Markets analyst Evan David Seigerman. In a note to clients, ...

The collapse followed Novo's downward revision of its 2025 outlook, citing weaker-than-expected international uptake .

The stock fell as much as 30% after it cut its guidance. The pharma giant named a new CEO in hopes of reviving growth., ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday ...

The lowered sales outlook for 2025 is driven by lower growth expectations for the second half of 2025. This is related to lower growth expectations for Wegovy ® in the US obesity market, lower growth ...

Novo Nordisk named Maziar Mike Doustdar as its new chief executive on Tuesday, relying on an experienced company insider to ...

Shares in Danish drugmaker Novo Nordisk were down nearly 20% in pre-market trading Tuesday morning after the company cuts its ...

U.S.-listed shares of Novo Nordisk sank in premarket trading Tuesday after the Danish drugmaker cut its full-year outlook and ...

Desai believes it's a "good time for fixed income," but wants to see more realistic investor expectations. Generations out there in the past got accustomed to getting just 1% -2.5% for investing in 10 ...

Stock futures are pointing to a higher open on Tuesday, putting major indexes on track to hit new record highs, as investors ...

Shares in Novo Nordisk plunged by as much as 30% after the Danish drugmaker cut its guidance and named a new chief executive, pinning its hopes on a company veteran to revive growth.

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...